Avicenna Journal of Medicine

REVIEW ARTICLE
Year
: 2019  |  Volume : 9  |  Issue : 4  |  Page : 123--128

Antithrombotic therapy in patients with atrial fibrillation and coronary artery disease


Abdelmoniem Moustafa, Mohammad Ruzieh, Ehab Eltahawy, Saima Karim 
 Department of Internal Medicine and Cardiology, University of Toledo Medical Center, Toledo, Ohio, USA

Correspondence Address:
Dr. Abdelmoniem Moustafa
Departments of Internal Medicine and Cardiology, University of Toledo Medical Center, Toledo, Ohio.
USA

Atrial fibrillation and coronary artery disease are commonly coexisting conditions that necessitate the use of an oral anticoagulant as well as dual antiplatelet therapy. Commonly referred to as triple oral antithrombotic therapy (TT), this helps prevent ischemic stroke and myocardial infarction but comes at the expense of an increased risk of bleeding. There is a growing body of evidence that the omission of aspirin from TT has the same preventive efficacy in terms of major adverse cardiacvascular and cerebrovascular events (MACCE) with significantly lower bleeding events. The combination of antiplatelet agents and direct oral anticoagulants (DOAC) is a matter of ongoing research. However, initial studies showed favorable safety profile of DOAC over vitamin K antagonist in combination with antiplatelet agents.


How to cite this article:
Moustafa A, Ruzieh M, Eltahawy E, Karim S. Antithrombotic therapy in patients with atrial fibrillation and coronary artery disease.Avicenna J Med 2019;9:123-128


How to cite this URL:
Moustafa A, Ruzieh M, Eltahawy E, Karim S. Antithrombotic therapy in patients with atrial fibrillation and coronary artery disease. Avicenna J Med [serial online] 2019 [cited 2019 Nov 12 ];9:123-128
Available from: http://www.avicennajmed.com/article.asp?issn=2231-0770;year=2019;volume=9;issue=4;spage=123;epage=128;aulast=Moustafa;type=0